跳至主要内容
临床试验/NCT02357771
NCT02357771已完成3 期

Topical Application of Probiotic Lozenge to Reduce Streptococcus Mutans in Plaque Around Orthodontic Brackets

Next Gen Pharma India Pvt. Ltd.1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2015年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
Changes in the levels of streptococcus Mutans in the plaque around orthodontic brackets.

研究概览

简要总结

Advances in orthodontics have improved the quality of appliances and treatment protocols, raising the standard of patient care. However, enamel demineralization is still a problem associated with orthodontic treatment, leading to the formation of white spot lesions; this is a grave concern to orthodontists and patients.

The overall prevalence of white spot lesions among orthodontic patients has been reported to be between 4.9% and 84%.1 When basic oral hygiene is poor, orthodontic appliances create areas of plaque stagnation, especially around brackets, bands, wires, and other attachments. Levels of acidogenic bacteria, present in the plaque, notably Streptococcus mutans (S mutans), are higher in orthodontic patients than in non-orthodontic patients.

This causes demineralization around the brackets and leads to white spot lesions. They are most prevalent around the cervical region of bands in the posterior region, whereas in the anterior region, the lateral incisors in both arches, followed by the canines, are most commonly affected.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Orthodontic treatment with the straight wire appliance (MBT, 0.022-in slot; 3M Unitek, Monro- via, Calif).
  • Complete permanent dentition (excluding third molars).
  • No chewing gum or mouthwash used in the last week and during the study.
  • Habit of brushing twice daily with fluoride toothpaste.

排除标准

  • Patient with poor periodontal condition.
  • Patient with known medical condition e.g. subacute bacterial endocarditis, diabetes, valvular disease, anemia etc.

研究组 & 干预措施

Placebo Arm

Placebo Comparator

Placebo Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)

干预措施: Placebo (Drug)

Probiotic Arm

Experimental

Lactobacillus brevis CD2 Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2

干预措施: Probiotic (L. brevis CD2 lozenges) (Drug)

结局指标

主要结局

Changes in the levels of streptococcus Mutans in the plaque around orthodontic brackets.

时间窗: 30 days

次要结局

未报告次要终点

研究者

发起方
Next Gen Pharma India Pvt. Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Probiotic Lozenge Reduce Streptococcus Mutans in... | 临床试验